Trametinib-Associated Bradycardia

Am J Ther. 2019 Sep/Oct;26(5):e657-e659. doi: 10.1097/MJT.0000000000000862.

Authors

Luai Alhazmi¹, Mohammad M Karim², Mohammad Al-Sarie³, Roland Skeel⁴, Saima Karim¹

Affiliations

¹ Division of Cardiovascular Medicine, University of Toledo, Toledo, OH.
² Division of Cardiovascular Medicine, New York Medical Center, Valhalla, NY.
³ Department of Internal Medicine, University of Toledo, Toledo, OH.
⁴ Division of Hematology and Oncology, University of Toledo, Toledo, OH.

PMID: 31241492
DOI: 10.1097/MJT.0000000000000862

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Administration, Oral
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
Bradycardia / chemically induced*
Bradycardia / diagnosis
Bradycardia / drug therapy
Cardiotonic Agents / therapeutic use
Dopamine / therapeutic use
Electrocardiography, Ambulatory
Humans
Imidazoles / administration & dosage
Male
Melanoma / drug therapy
Middle Aged
Oximes / administration & dosage
Protein Kinase Inhibitors / administration & dosage
Protein Kinase Inhibitors / adverse effects*
Pyridones / administration & dosage
Pyridones / adverse effects*
Pyrimidinones / administration & dosage
Pyrimidinones / adverse effects*
Skin Neoplasms / drug therapy
Treatment Outcome

Substances

Cardiotonic Agents
Imidazoles
Oximes
Protein Kinase Inhibitors
Pyridones
Pyrimidinones
trametinib
dabrafenib
Dopamine